COVID-19Advances in clinical outcomes: What we have learned during the COVID-19 pandemic
Key words
SARS-CoV-2
COVID-19
asthma
primary immunodeficiency
biologics
Abbreviations used
COVID-19
Coronavirus disease 2019
CVID
Common variable immunodeficiency
CXCL
CXC motif chemokine ligand
EUA
Emergency use authorization
HR
Hazard ratio
IFN
Interferon
JAK
Janus kinase
OR
Odds ratio
PEG
Polyethylene glycol
PID
Primary immunodeficiency
RCT
Randomized controlled trial
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
TLR
Toll-like receptor
Cited by (0)
This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant no. R01DK130465 to J.C.) and the National Institute of Allergy and Infectious Diseases (grant no. R01AI139633-04S1 to J.C.; grant no. T32AI007512 to B.L. and A.A.N.).
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
© 2021 American Academy of Allergy, Asthma & Immunology